- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
GSK submits sBLA seeking expanded indication for Flulaval Quadrivalent
3 February 2016 • Author: Victoria White
GSK has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Flulaval Quadrivalent (Influenza Vaccine).
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses, in persons three years of age and older. The submission seeks an expanded indication for children six months through 35 months of age. With this approval, providers would be able to use the same dose of Flulaval Quadrivalent (15 ug of hemagglutinin per virus strain in 0.5 mL) to cover all eligible persons from six months and up.
The sBLA application is based on one Phase III pivotal study and three supportive clinical studies conducted in children six months through 35 months of age.
GSK has submitted for presentation the results of the pivotal study to the Paediatric Academic Societies for their annual meeting later this year.
According to the US Centers for Disease Control and Prevention (CDC), the flu is more dangerous than the common cold for children. Severe flu complications are most common in children under the age of two years. Each year, many children get sick with seasonal influenza and some of those illnesses result in death. On average 20,000 children under the age of five are hospitalised in the US because of influenza complications. The CDC recommends that everyone aged six months and older get a seasonal flu vaccine.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics